📊 MXCT Key Takeaways
Is Maxcyte, Inc.. (MXCT) a Good Investment?
MaxCyte demonstrates strong revenue growth of 57.6% YoY and exceptional gross margins of 83.7%, indicating viable unit economics. However, the company is burning cash operationally at -8.2M annually with a -64.1% operating margin, leaving only ~1.8 years of cash runway at current burn rates. Without a clear path to profitability, the company will likely require dilutive capital raises, making fundamental risk outweigh near-term growth momentum.
MaxCyte shows strong top-line momentum and excellent gross margins, supported by a debt-free balance sheet and ample liquidity. However, heavy operating losses and significant cash burn indicate a long path to profitability and potential financing risk if efficiency does not improve. Watch for operating leverage to emerge as revenue scales before upgrading the outlook.
Maxcyte, Inc.. Key Strengths (MXCT)
- Strong revenue growth of 57.6% YoY demonstrating market demand
- Exceptional gross margin of 83.7% showing strong pricing power and unit economics
- Zero debt with 167.9M in stockholders' equity providing financial flexibility
- Rapid revenue growth (+57.6% YoY)
- High gross margin (~81%) signaling strong unit economics
- Strong liquidity and no debt (current ratio 8.3x, D/E 0.0x)
MXCT Stock Risks: Maxcyte, Inc.. Investment Risks
- Negative operating cash flow of -8.2M annually with limited cash runway (~1.8 years at current burn rate)
- Operating margin of -64.1% indicates operating expenses far exceed revenue; path to profitability unclear
- Net income flat YoY despite 57.6% revenue growth shows losses not improving despite scaling
- Likely need for dilutive capital raise in near term given cash burn trajectory
- Sustained operating losses and large FCF burn (-109.5% margin)
- Potential dilution if external financing becomes necessary
- Execution risk in achieving operating leverage (negative ROE/ROA)
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Operating expense growth rate relative to revenue growth
- Cash balance and runway remaining before forced capital raise
- Gross margin sustainability and ability to maintain pricing power
- Operating margin (OpEx as % of revenue)
- Free cash flow and liquidity runway
Maxcyte, Inc.. (MXCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.04x current ratio provides a solid financial cushion.
MXCT Profit Margin, ROE & Profitability Analysis
MXCT vs Healthcare Sector: How Maxcyte, Inc.. Compares
How Maxcyte, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Maxcyte, Inc.. Stock Overvalued? MXCT Valuation Analysis 2026
Based on fundamental analysis, Maxcyte, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Maxcyte, Inc.. Balance Sheet: MXCT Debt, Cash & Liquidity
MXCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Maxcyte, Inc..'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
MXCT Revenue Growth, EPS Growth & YoY Performance
MXCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.5M | -$4.8M | $-0.04 |
| Q3 2025 | $4.6M | -$9.4M | $-0.11 |
| Q2 2025 | $5.0M | -$9.4M | $-0.09 |
| Q1 2025 | $5.6M | -$9.5M | N/A |
| Q3 2024 | $4.2M | -$9.4M | $-0.11 |
| Q2 2024 | $5.0M | -$9.4M | $-0.09 |
| Q1 2024 | $5.0M | -$9.5M | N/A |
| Q3 2023 | $4.2M | -$4.1M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Maxcyte, Inc.. Dividends, Buybacks & Capital Allocation
MXCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Maxcyte, Inc.. (CIK: 0001287098)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MXCT
What is the AI rating for MXCT?
Maxcyte, Inc.. (MXCT) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MXCT's key strengths?
Claude: Strong revenue growth of 57.6% YoY demonstrating market demand. Exceptional gross margin of 83.7% showing strong pricing power and unit economics. ChatGPT: Rapid revenue growth (+57.6% YoY). High gross margin (~81%) signaling strong unit economics.
What are the risks of investing in MXCT?
Claude: Negative operating cash flow of -8.2M annually with limited cash runway (~1.8 years at current burn rate). Operating margin of -64.1% indicates operating expenses far exceed revenue; path to profitability unclear. ChatGPT: Sustained operating losses and large FCF burn (-109.5% margin). Potential dilution if external financing becomes necessary.
What is MXCT's revenue and growth?
Maxcyte, Inc.. reported revenue of $9.7M.
Does MXCT pay dividends?
Maxcyte, Inc.. does not currently pay dividends.
Where can I find MXCT SEC filings?
Official SEC filings for Maxcyte, Inc.. (CIK: 0001287098) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MXCT's EPS?
Maxcyte, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MXCT's fundamental grade?
Based on our AI fundamental analysis in May 2026, Maxcyte, Inc.. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MXCT stock overvalued or undervalued?
Valuation metrics for MXCT: ROE of -2.8% (sector avg: 15%), net margin of -49.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MXCT's AI grade for 2026?
Our dual AI analysis gives Maxcyte, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MXCT's free cash flow?
Maxcyte, Inc..'s operating cash flow is $-8.2M, with capital expenditures of $72.0K. FCF margin is -85.4%.
How does MXCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -49.2% (avg: 12%), ROE -2.8% (avg: 15%), current ratio 12.04 (avg: 2).